Calcioprotein Particles
Balancing Mineral Homeostasis and Vascular Pathology

Anton G. Kutikhin,* Lian Feenstra,* Alexander E. Kostyunin, Arseniy E. Yuzhalin, Jan-Luuk Hillebrands, Guido Krenning

ABSTRACT: Hypercalcemia and hyperphosphatemia associate with an elevated risk of cardiovascular events, yet the pathophysiological basis of this association is unclear. Disturbed mineral homeostasis and the associated hypercalcemia and hyperphosphatemia may result in the formation of circulating calcioprotein particles (CPPs) that aggregate the excessive calcium and phosphate ions. If not counteracted, the initially formed harmless amorphous spherical complexes (primary CPPs) may mature into damaging crystalline complexes (secondary CPPs). Secondary CPPs are internalized by vascular cells, causing a massive influx of calcium ions into the cytosol, leading to a proinflammatory response, cellular dysfunction, and cell death. Although the pathophysiological effects induced by CPPs in vascular cells receive increasing attention, a complete picture of how these particles contribute to the development of atherosclerosis and vascular calcification remains elusive. We here discuss existing knowledge on CPP formation and function in atherosclerosis and vascular calcification, techniques for investigating CPPs, and models currently applied to assess CPP-induced cardiovascular pathogenesis. Lastly, we evaluate the potential diagnostic value of serum CPP measurements and the therapeutic potential of anti-CPP therapies currently under development.

GRAPHIC ABSTRACT: A graphic abstract is available for this article.

Key Words: atherosclerosis ■ calcium ■ homeostasis ■ hypercalcemia ■ hyperphosphatemia ■ vascular calcification

Calcioprotein particles (CPPs) are blood-borne circulating particles formed of a combination of calcium phosphate and protein. Their clinical importance stems from the observation that circulating CPP levels are elevated in patients with chronic kidney disease where vascular calcification develops earlier compared to healthy subjects. Indeed, increased circulating CPP levels associate with arterial stiffness and the development and progression of calcific uremic arteriopathy, atherosclerosis, and vascular calcification. Moreover, the propensity of serum to form CPPs is associated with the occurrence of cardiovascular events and mortality. Albeit the pathophysiological effects of CPPs receive increasing attention, mechanistic insight into how these particles contribute to the development of atherosclerosis and vascular calcification remains elusive. In this review, we discuss existing knowledge on CPP formation and function in atherosclerosis and vascular calcification, the techniques to investigate CPPs, and models currently applied to assess CPP-induced cardiovascular pathogenesis.

CALCIUM AND PHOSPHATE HOMEOSTASIS AND THE GENERATION OF CPPS

Serum calcium and phosphate levels are tightly regulated in the human body. Calcium and phosphate metabolism includes their intestinal absorption, deposition and resorption from the bone, and renal reabsorption, regulated by...
calcitropic and phosphotrophic factors (reviewed in Rendkema et al,16 Peacock,17 Peacock,18 Blaine et al19). Mechanisms maintaining calcium and phosphate homeostasis are redundant and interconnected,18 and their dysregulation may result in hypercalcemia and hyperphosphatemia as well as extraskeletal calcifications, including vascular calcifications.12,18

A network of endogenous inhibitors, with distinct mechanisms of action, prevents and inhibits the formation of extraskeletal calcifications.20 First, the prevention of bone resorption, the decrease in calcium and phosphate reabsorption by the kidneys, and the inhibition of calcium phosphate crystal growth all inhibit extraskeletal calcification. Osteoprotegerin is a decoy RANKL (receptor for the receptor activator of nuclear factor κB ligand)21 precluding osteoclastic differentiation, activation, and bone resorption.22,23 Osteopontin inhibits osteoclastic differentiation and bone resorption, but its vascular expression promotes mineral resorption via unknown mechanisms.24–26 Klotho is a coreceptor for fibroblast growth factor 23 that abates phosphate reabsorption in kidney proximal tubules and biosynthesis of calcitriol, thereby reducing renal tubular calcium reabsorption and intestinal calcium and phosphate absorption.27

Furthermore, inorganic pyrophosphate hinders the nucleation and crystallization of amorphous calcium and inhibits the growth of mature hydroxyapatite crystals.20

Second, circulating calcium scavengers buffer the amount of free calcium available for extraskeletal calcification. Albumin binds ionized calcium (Ca2+) via its negatively charged amino acids distributed on the surface of the tertiary protein structure, scavenging Ca2+ from the micro-environment.1 Similarly, osteonectin scavenges Ca2+ via multiple negatively charged amino acids focused on specific domains, for example, EF-hand (helix-loop-helix) domain.28

Third, CPPs scavenge both free Ca2+ and phosphate (PO43−) ions and sequester minerals available for extraskeletal calcification. CPPs are blood-borne spon¬
gous carbonate-hydroxyapatite particles, 50 to 500 nm in diameter,20,29 that adsorb proteins from their environment.31,32 Fetuin-A, MGP (matrix γ-carboxylated glutamate–rich protein) and GRP (γ-carboxylated glutamate–rich protein) scavenge Ca2+ and PO43− ions from the serum and complex these into clusters of protein and amorphous calcium phosphate (Ca10[PO4]6[OH]2)1,33,34,36 Fetuin-A scavenges serum Ca2+ and PO43− via its negatively charged extended β-sheet within the amino-terminal cystatin-like D1 domain1,32 and stabilizes nascent clusters of calcium phosphate in its monomeric form33 (Figure 1A). MGP and GRP contain negatively charged γ-carboxylated glutamate residues34,35 which bind both Ca2+ and calcium-containing compounds (Figure 1A).36–38 The interaction between fetuin-A and MGP integrates calcium and phosphate clusters into amorphous proteinaceous secondary CPPs containing calcium hydroxyapatite (Ca10[PO4]6[OH]2) by a process called amorphous-to-crystalline transition.

### Nonstandard Abbreviations and Acronyms

| Abbreviation | Description |
|--------------|-------------|
| BMP          | bone morphogenetic protein |
| Ca2+         | ionized calcium |
| CaSR         | calcium-sensing receptor |
| CKD          | chronic kidney disease |
| CMVs         | calcifying microvesicles |
| CPPs         | calciprotein particles |
| ECs          | endothelial cells |
| eNOS         | endothelial nitric oxide synthase |
| ESRD         | end-stage renal disease |
| GRP          | γ-carboxylated glutamate–rich protein |
| HAP          | hydroxyapatite |
| IL           | interleukin |
| MGP          | matrix γ-carboxylated glutamate protein |
| MSR          | macrophage scavenger receptor |
| MSX          | homeobox transcription factor muscle |
| NF-κB        | nuclear factor kappa B |
| RANKL        | receptor activator of nuclear factor κB ligand |
| RUNX         | runt-related transcription factor |
| SOX          | sex-determining region Y-box |
| TACT         | trial to assess chelation therapy |
| TLR          | toll-like receptor |
| TNF          | tumor necrosis factor |
| VSMCs        | vascular smooth muscle cells |

### Highlights

- This review discusses the contribution of calciprotein particles to the pathogenesis of atherosclerosis and vascular calcifications. The important determinants of calciprotein particle formation and the pathogenic processes wherein calciprotein particles are involved are highlighted.
- Calciprotein particles are internalized by vascular cells, causing a massive influx of calcium ions into the cytosol, leading to a proinflammatory response, cellular dysfunction, and cell death.
- Calciprotein particles are a modifiable risk factor for the development of cardiovascular events.
- Pioneering anti-calciprotein particle therapies reduce the risk of cardiovascular events.
Figure 1. Calciprotein particle (CPP) formation and pathophysiological mechanisms.
In the blood, Ca²⁺ and PO₄³⁻ form complexes of calcium phosphate that can be scavenged by fetuin-A via the β-sheet of the amino-terminal cystatin-like D1 domain, which contains multiple negatively charged amino acids. MGP (matrix γ-carboxylated glutamate protein) and GRP (γ-carboxylated glutamate-rich protein) scavenge calcium phosphate via their negatively charged amino acids in the γ-carboxylated glutamate residues. Additionally, MGP and GRP scavenge PO₄³⁻ via the phosphorylation of serine residues (A). The interaction between fetuin-A and MGP integrates calcium phosphate into amorphous spherical particles named primary CPP (B). These primary CPP may ripe into highly crystalline CPP (secondary CPP) under conditions of hypercalcemia and hyperphosphatemia (C). (Continued)
BRIEF REVIEW - VB

medial arterial calcifications and may prematurely and phosphate homeostasis as mice lacking either proline transition need further investigation. The key determinants of amorphous-to-crystalline transition are mice lacking either proline transition. The key determinants of amorphous-to-crystalline transition need further investigation.

Exogenous fetuin-A may act as an inhibitor of amorphous-to-crystalline transition. Exogenous fetuin-A supplementation inhibits the development of calcified thrombi in fetuin-A–deficient mice, confirming its relevance to vasculopathy. Expectedly, serum Ca\(^{2+}\), PO\(_4^{3-}\) levels all associate with the development of vascular pathology.

Hereinafter, it must be noted that proteinaceous CPPs should be clearly distinguished from inorganic calcium phosphate crystals, although an identical mineral composition of these entities may evoke similar downstream events.

**CPPs in Cardiovascular Pathophysiology**

**Internalization, Cell Death and Proinflammatory Signaling**

CPPs exert considerable cytotoxic effects on multiple vascular and valvular cell types, including vascular endothelial cells (ECs), vascular smooth muscle cells (VSMCs), adventitial fibroblasts, valve interstitial cells, and valvular ECs.

Internalization of CPPs is an active process that may occur via clathrin-mediated endocytosis, involving MSR (macrophage scavenger receptor 1 scavenger receptors and actin polymerization) and crystallinity greatly impact internalization. CPP shape and crystallinity greatly impact internalization, and different cell types have distinct internalization efficiencies. Macrophages preferentially internalize secondary CPPs, whereas ECs preferentially internalize primary CPPs.

The molecular basis behind these distinct internalization patterns is currently unknown but may reflect distinct receptors for primary and secondary CPPs. Indeed, knockdown of the MSR1 gene or blockade of the MSR1 receptor in macrophages diminishes the internalization of secondary CPPs without affecting the internalization of primary CPPs. Furthermore, the CaSR (calcium-sensing receptor) is expressed on a variety of vascular cells, including ECs, smooth muscle cells, and monocytes and offers an alternative route for CPP internalization. Blood monocytes internalize secondary CPPs via the CaSR in a Ca\(^{2+}\) concentration-dependent manner, but independently of PO\(_4^{3-}\). Of note, the internalization of inorganic calcium phosphate crystals is also accomplished by clathrin-mediated endocytosis and macropinocytosis, suggesting that CPPs and calcium phosphate crystals use similar internalization routes.

Inorganic calcium phosphate crystals induce cell death via Ca\(^{2+}\)-dependent mitochondrial outer membrane permeabilization. Controversy exists as to the exact mechanism of the cytosolic calcium influx; some experimental results indicate mild lysosome membrane permeabilization; other studies report severe lysosomal rupture due to the osmotic difference between the crystal-carrying lysosomes and the cytosol. CPPs also induce cell death in a variety of vascular cells, albeit to a lesser extent, and it is tempting to speculate that CPP-induced cell death occurs via similar mechanisms of the cytosolic calcium influx; some experimental results indicate mild lysosome membrane permeabilization; other studies report severe lysosomal rupture due to the osmotic difference between the crystal-carrying lysosomes and the cytosol. Nonetheless, cleavage of caspase-3 and caspase-9 following CPP internalization by vascular cells implies a central role for intrinsic apoptosis and CPP-induced cell death remains unclear and may differ between primary and secondary CPPs, as these have distinct crystallinity and therefore solubility in lysosomes. Nonetheless, cleavage of caspase-3 and caspase-9 following CPP internalization by vascular cells implies a central role for intrinsic apoptosis (Figure 1D).

CPPs induce expression and secretion of proinflammatory cytokines, including IL (interleukin)-1β, IL-6, IL-8, TNF, and others.
and TNF (tumor necrosis factor)-α, potentially via the Ca²⁺-reactive oxygen species-NFκB-axis or inflammasome activation. Knockdown of the toll-like receptor 4 (TLR4), RANKL, or CaSR gene abrogates secretion of TNF-α and IL-1β after CPP exposure, indicating a paramount role for TLR4, RANKL, and CaSR in CPP-induced cytokine responses. Primary CPPs promote the release of IL-1β, whereas secondary CPPs induce TNF-α secretion, suggesting that primary and secondary CPP have distinct receptor binding affinities and evoke distinct signaling cascades. Nonetheless, inflammasome activation is required for CPP-induced cytokine expression, as blocking inflammasome assembly abrogates overall cytokine expression (Figure 1D).

Endothelial Dysfunction

The endothelium represents a barrier between circulating CPPs and underlying vascular tissue and are the first cell population exposed to CPPs upon their formation. Endothelial inflammatory activation and endothelial dysfunction are triggered by proatherogenic and proinflammatory signaling molecules and key in the development of atherosclerosis and vascular calcification (reviewed in Gimbrone and Garcia-Cardeña). Another sequel of the osteochondrogenic dedifferentiation of VSMCs is excessive production of core matrisome components (ie, collagens, proteoglycans, and glycoproteins) and extracellular matrix regulators (ie, matrix metalloproteinases and metalloproteinases) that contribute to blood vessel remodeling.

Endothelial dysfunction is defined as the pathological state wherein vasostenosis occurs as a consequence of an imbalance in the relative contribution of endothelium-derived relaxing and contracting factors. It is well established that proatherogenic signaling molecules, including oxidized lipids, evoke endothelial dysfunction, which may culminate in hypertensive responses. CPP number and serum calcification propensity both associate with blood pressure, implying CPP may also induce endothelial dysfunction. Moreover, endothelial dysfunction associates with serum fetuin-A levels and sevelamer—a calcium binder that reduces circulating CPPs—preserves endothelial-dependent vasorelaxation and maintains endothelial integrity in mice with chronic kidney disease. One possible mechanism by which CPP may induce endothelial dysfunction is by reducing NO bioavailability, either by repressing the expression or activity of eNOS (endothelial NO synthase), or by the ROS-mediated scavenging of NO. Alternatively, CPPs might increase levels of asymmetrical dimethylarginine, an endogenous inhibitor of NO. The exact mechanism by which CPPs induce endothelial dysfunction is unknown and warrants further investigation.

Osteochondrogenic dedifferentiation

Vascular calcification is associated with the osteochondrogenic dedifferentiation of VSMCs, induced by the proatherogenic and proinflammatory milieu. The osteochondrogenic dedifferentiation of VSMCs is controlled by distinct transcription factors like Runx2 (runt-related transcription factor 2), Osterix, MSX2 (homeobox transcription factor muscle segment homeobox 2), and SOX9 (sex-determining region Y-box 9; reviewed in Durham et al). Activation of the osteochondrogenic transcription machinery culminates in decreased expression of contractile proteins (eg, α-smooth muscle actin, smooth muscle myosin heavy chain, smoothelin, calponin) and increased expression of osteogenic markers (osteopontin, osteocalcin, alkaline phosphatase, and collagens).

Another sequela of the osteochondrogenic dedifferentiation of VSMCs is excessive production of core matrisome components (ie, collagens, proteoglycans, and glycoproteins) and extracellular matrix regulators (ie, matrix metalloproteinases and metalloproteinases) that contribute to blood vessel remodeling. This further potentiates the osteochondrogenic dedifferentiation process, aggravating impairment of vascular homeostasis and resulting in a stable proatherogenic microenvironment and increased vascular stiffness.

VSMC osteochondrogenic dedifferentiation may be induced by a plethora of factors, including oxidized lipids and oxidative stress. Inflammatory cytokines, growth factors, hormones, vitamin D, and calcium phosphate crystals. Hence, the use of HMG-CoA (β-hydroxy β-methylglutaryl-CoA) reductase inhibitors—more commonly known as statins—has received high interest as potential therapeutic in vascular calcification because of their lipid-lowering and anti-inflammatory effects. The inhibition of cholesterol synthesis diminishes cAMP-dependent matrix calcification by VSMC and mitigates inflammation-induced artery calcification in rodents via mechanisms including the lowering of plasma Ca²⁺ levels, the suppression of autophagy, the prevention of phosphate-induced VSMC apoptosis, and microarchitectural changes in calcium deposits. Yet, clinical studies on the use of statin therapy in vascular calcification have been discordant: statins are reported to promote, suppress, or have no effect on vascular calcification. These discrepancies may be explained by the interaction between statins and BMP (bone morphogenic protein)-2 signaling in VSMC. The activation of BMP-2 signaling is a key event in vascular calcification as it evokes the expression of the osteochondrogenic transcription factors Runx2 and Osterix. Indeed, the loss of the BMP-2 inhibitory molecule Smad6 culminates in the aggravation of vascular calcification. Statins induce the expression of BMP-2 and BMP receptor II in VSMC, which may change the calcification process. Indeed, statins promote macrocalcification of atherosclerotic plaques, irrespective of their plaque-regressing effects. As macrocalcifications associate with plaque stability, these
observations may explain why statins decrease cardiovascular risk, despite increasing vascular calcification.3,174 Thus, a deeper understanding of the mechanisms underlying vascular calcification is warranted and the clinical need for new treatments remains.

It is well accepted that CPPs promote calcification by VSMCs.2,50,62,125 However, controversy exists on the induction of osteochondrogenic dedifferentiation by CPPs. To illustrate, some studies report reduced osteochondrogenic differentiation when the formation of secondary CPPs is blocked50 or CPPs are removed from serum,2 whereas others fail to identify osteochondrogenic gene signatures in the calcified lesions.45

Mechanistic insight on the interference of CPPs on the osteochondrogenic dedifferentiation of VSMC is limited, yet the elimination of CPPs from the serum of patients with end-stage renal disease (ESRD) reduces the serum capacity to induce osteochondrogenic differentiation and abrogates its procalcific capacity.3 Likewise, the addition of CPPs derived from ESRD patients to the serum of healthy blood donors promotes the osteochondrogenic dedifferentiation of VSMCs.2 CPP-induced osteochondrogenic dedifferentiation appears restricted to secondary CPPs, as inhibiting amorphous-to-crystalline transition prevents VSMC calcification.125 In VSMCs, CPPs provoke an increase in cell-bound calcium50,126 and may induce osteochondrogenic differentiation via a multitude of mechanisms (Figure 1E). First, CPPs induce the expression and secretion of TNFα by VSMC,50 which can trigger osteochondrogenic dedifferentiation via the MSX2127 and AP-1 (activator protein 1)128 transcriptional regulators augmenting the expression of Runx2. Second, CPPs may provoke the expression and secretion of BMP-2 by VSMC,103 which induces osteochondrogenic dedifferentiation via increased phosphate transport,129 resulting in endoplasmic reticulum stress and the activation of osteogenic transcription factor XBP1 (x-box binding protein 1).130 Third, CPPs induce VSMC oxidative stress50 which activates a multitude of downstream signaling cascades (eg, Akt [Ak-strain transforming], p38 MAPK [mitogen-activated protein kinase], and NfκB) enhancing the transcriptional activation of the osteochondrogenic differentiation program.131–134 Alternatively, CPPs promote the secretion of IL-6 from EC,64 which may drive the osteochondrogenic differentiation of VSMC in a STAT3 (signal transducer and activator of transcription 3)-dependent manner.135

**Calcifying Microvesicles**

Vascular calcification occurs in the extracellular space126,127 and is initiated by the secretion of calcifying microvesicles (CMVs) from VSMC128 and plaque macrophages,129 which represent nucleation sites for matrix calcification.140 Cell-derived CMVs are distinct from blood-borne CPPs. CMVs and CPPs differ in origin, size, the presence of membranous proteins and lipids, and crystallinity (Table). CMVs are a heterogeneous group of secreted vesicles, including matrix vesicles and exosomes,157,164,165 which function to maintain mineral homeostasis. Under physiological conditions, CMVs contain inhibitors of calcification, whereas under pathogenic conditions, promoters of calcification are present.158,169,166,167 Once released in the extracellular space, CMV aggregate by annexin-dependent tethering158,160 and bind to matrix collagens161 to form nucleation sites for calcification, culminating in microcalcifications,140 which may fuse to form macrocalcifications within the vessel wall.168

CPPs may influence CMV-mediated calcification in several ways. First, CPPs induce apoptosis of VSMC59 and apoptotic bodies form a nidus for calcification.159,170 Second, CPPs cause a rise in cytoplasmic Ca2+129 and high cytosolic Ca2+ levels in VSMC result in the formation of procalcifying CMVs158 (Figure 1E). Third, CPPs can be isolated from calcified atherosclerotic lesions32 wherein CPPs may fuse to and integrate into the developing microcalcifications. How CPPs interfere with CMV-mediated calcification is understudied and a complete picture is lacking. Nonetheless, serum calcification propensity and CPP maturity associate with calcified lesion size,8,171 suggesting an interaction that deserves further evaluation.

**Perivascular Adipocytes and Adventitial Fibroblasts**

It is increasingly recognized that the perivascular adipose tissue actively contributes to atherogenesis129,173 and vascular calcification.174,175 The perivascular adipose tissue, wherein perivascular adipocytes reside, is a highly metabolic tissue, which secretes a plethora of paracrine signaling molecules, including vasoactive and immunomodulatory factors.176–178 Proatherogenic actions of perivascular adipocytes include the secretion of proinflammatory cytokines,179 the recruitment of inflammatory cells into the vessel wall,180 the induction of smooth muscle cell proliferation in the neointima,181 and the activation of adventitial fibroblasts,182 all facilitating atherogenesis. Moreover, inflammatory activation of the perivascular adipose tissue is associated with decreased plaque stability, vascular calcification, and an increased cardiovascular risk score.174 Adventitial fibroblasts also contribute to atherogenesis183 and vascular calcification.184 Stimulated by atherogenic and proinflammatory signaling molecules, adventitial fibroblasts acquire a motile myofibroblastic phenotype185,186 and migrate into the forming neointima.167,188 Myofibroblasts are professional extracellular matrix producing cells, that facilitate neointimal growth by the secretion of collagens and other matrix components.189 Moreover, myofibroblasts secrete a variety of...
proinflammatory cytokines,\textsuperscript{190} which enhance endothelial dysfunction, inflammatory cell recruitment into the neo-intima,\textsuperscript{191–193} and smooth muscle cell proliferation.\textsuperscript{186} Notably, vascular calcification may not only occur in the intima or media but also occurs in the adventitia,\textsuperscript{194} where—under conditions of hypercalcemia and hyperphosphatemia—adventitial myofibroblasts actively contribute to calcium deposition.\textsuperscript{19}

Table. Characteristics of the Various Procalcifying Particles: CaP, CPPs, and CMVs

| Particle | Aliases | Origin | Serum, Tissue, Protein | N/S | Size, nm | Organic profile | Mineral profile | Biologic effect | References |
|----------|---------|--------|------------------------|-----|---------|----------------|----------------|----------------|------------|
| CaP      | Calcium pyrophosphate dihydrate microcrystals | ? | S | 1–30 | − | − | C | HAP | CPP induce inflammatory signaling in macrophages | 70 |
| Hydroxyapatite crystals, hydroxyapatite particles | ? | S | 15–200 | − | − | C | HAP | CaP crystals induce EC toxicity and activation, osteochondrogenic dedifferentiation, and calcification | 52,58 |
| Nanoparticulate apatite, nanosized hydroxyapatite, calcium phosphate nanoparticles | ? | S | 100–300 | − | − | C | cHAP, HAP | CaP crystals induce VSMC toxicity | 59–61 |
| CPPs | CPPs | Serum | N/S | 30–250 | FetA, Alb, ApoA, GRP, MGP | − | A: CPP-I cHAP, HAP; C: CPP-II Monetite | CPP induce inflammatory signaling, osteochondrogenic dedifferentiation and calcification | 1,2,41,49,50, 55,56,125,126 |
| Calcium phosphate bions | Serum | N/S | 100–500 | FetA, Alb, ApoA | − | A: CPP-I cHAP, HAP; C: CPP-II Calcite | Calcium phosphate bions induce EC toxicity and intimal hyperplasia | 32,64 |
| Calcium phosphate (nano)particles | FetA | S | 30–200 | FetA | ? | A: CPP-I HAP; C: CPP-II | Calcium phosphate (nano) particles induce VSMC toxicity, but to a lesser extent than CaP | 31,63 |
| Calcium phosphate precipitates | Serum | N | ? | FetA | ? | ? | ? | Calcium phosphate precipitates levels associate with kidney function and vascular calcification | 141 |
| Calcifying nanoparticles, calcified nanoparticles | Serum and tissue | S | 20–1000 | ? | ? | ? | ? | Calcifying nanoparticles induce vascular occlusion and calcification | 62,142,143 |
| Fetuin-mineral complexes | FetA | S | ? | FetA, Alb, MGP | ? | ? | ? | Fetuin-mineral complex levels associate with osteoclast activity, bone resorption and vascular calcification | 144–149 |
| Mineralo-organic nanoparticles, mineralo-protein nanoparticles | Serum | S | 50–350 | FetA, Alb, ApoA | − | A: CPP-I HAP; C: CPP-II | Mineralo-organic nanoparticles induce inflammatory signaling | 40,66, 150–154 |
| Nanobacteria | Serum | S | 200–500 | FetA | ? | C | HAP | Nanobacteria are CPP and induce calcification | 51,155 |
| Protein-mineral complexes, protein-mineral particles | FetA | S | 50–250 | FetA, Alb, MGP | ? | A: CPP-I HAP; C: CPP-II | Protein-mineral complexes are endocytosed via SRA and induce inflammatory signaling | 53,54,156 |
| CMV | Calcifying extracellular vesicles, exosomes, Matrix vesicles | Cells (VSMC, Mph) | N | 30–300 | Annexins, CD9, CD63 | Membranous A | Ca$_2$(PO$_4$)$_3$ | CMV contain membranous lipids and amorphous calcium phosphate and localize at site of extracellular calcification | 138–140, 157–163 |

CPP: CPP-I: primary CPP; CPP-II: secondary CPP. ? indicates undetermined; −, negative; A, amorphous; Alb, albumin; C, crystalline; CaP, calcium phosphate crystal; cHAP, carbonate-hydroxyapatite (Ca$_{10}$(PO$_4$)$_6$(CO$_3$)$_3$(OH)$_2$); CMV, calcifying microvesicle; CPP, calciprotein particle; EC, endothelial cell; FetA, Fetuin-A; GRP, GLA-rich protein; HAP, hydroxyapatite (Ca$_{10}$(PO$_4$)$_6$(OH)$_2$); MGP, matrix γ-carboxylated glutamate protein; Mph, macrophage; N, natural origin; S, synthetic origin; SRA, scavenger receptor A; and VSMC, vascular smooth muscle cell.
Thus, perivascular adipocytes and adventitial fibroblasts actively contribute to atherogenesis and calcification. Hitherto, it is obscure if, and how CPPs might alter the behavior of these cells, and thus if CPPs mediate vascular pathogenesis via the perivascular adipose tissue or adventitia is unknown.

Dynamics of CPPs In Vivo

Serum CPPs can be isolated from a variety of (pre)clinical animal models and patient samples by (ultra)centrifugation, allowing analysis of their quantity, morphology, constituents, and subsequent study of their pathogenicity in vitro or in vivo models. Alternatively, CPP formation can be replicated in vitro by the supersaturation of serum-supplemented culture medium with calcium salts and phosphates. Primary and secondary CPPS are, respectively, synthesized by moderate and severe calcium/phosphate supersaturation of the culture medium or short- and long-term incubation. Notably, plaque-derived and synthesized CPPs show morphological and chemical resemblance.

Intravenous administration of CPPs into normolipidemic rats leads to aortic neointimal lesions in 30% to 40% of rats. Such preatherosclerotic niches are characterized by endothelial activation and the osteochondrogenic dedifferentiation of VSMCs, which produce abundant extracellular matrix, resembling that in human atherosclerotic plaque development. Combining CPP administration with balloon-induced vascular injury provokes development of intimal hyperplasia in 50% to 90% of animals, which vary in the presence of calcium phosphate deposits, suggesting a secondary hit (e.g., dyslipidemia or a chronic low-grade inflammation) as prerequisite for vascular calcification. Intravenous CPP administration has to date only been performed in normolipidemic animals, and it remains unclear whether CPPs are involved in the transition of developing plaques to calcified plaques. Administration of CPPs into atherosclerosis-prone apoE-deficient or low-density lipoprotein receptor–deficient mice with pre-established plaques could clearly answer this question and provide new insights into how CPPs affect atherosclerotic plaque calcification.

Despite the differences between the actions of primary and secondary CPPS in vitro, administration of either CPP type culminates in a similar outcome in vivo; that is, the prevalence of intimal hyperplasia and features of neointima formation by these 2 particle types is similar. It is tempting to speculate that the administered primary CPPS would mature into secondary CPPS in vivo, but evidence for this is lacking. Alternatively, the shape factor of toxicity of secondary CPPS may become negligible in vivo because of the adsorption of numerous serum proteins that smooth out the otherwise sharp particles. In keeping with this hypothesis, mass spectrometry analysis documented a similar protein composition for primary and secondary CPPS derived from various biofluids like serum and ascites, suggestive of an identical adsorption pattern.

The ability to fluorescently label CPPS by tagging fetuin-A or albumin with fluorescent dyes or generating a fluorescent-fusion fetuin-A/albumin and subsequently incorporating it into synthesized CPPS allows for their pharmacokinetic and pharmacodynamic evaluation (e.g., serum half-life, biodistribution, and clearance characteristics) as well as their cellular localization at sites of vascular injury. Alternatively, fluorescent bisphosphonate labeling of calcium phosphate offers a similar strategy to track CPPS in vivo. To illustrate, the intravenous administration of fluorescently labeled CPPS in healthy normolipidemic mice suggests that CPPS have a relatively short serum half-life and are rapidly cleared by the liver and spleen. In mice deficient in the macrophage scavenger receptor class A/macrophage receptor with a collagenous structure, administered CPPS did not accumulate in liver Kupffer cells or spleen macrophages, suggesting that clearance of CPPS is largely dependent on macrophage uptake. Furthermore, in a mouse model of calcified atherosclerosis, fluorescently labeled CPPS accumulate in the vessel lumen and plaque area and colocalize to the endothelium and macrophages. No CPPS were found in the arterial wall, suggesting that CPPS did not associate with VSMCs. Noteworthy, however, is that the fluorescence intensity of CPPS critically depends on the maturity of the particles and the extent of crystallinity and may not provide a sufficiently strong signal for complete in vivo imaging.

Although investigations on the in vivo effects of CPPS on the vasculature are in their infancy, development of in vivo imaging tools to assess the dynamics of CPPS, their distribution, and detection of the cell types they associate with, will undoubtedly increase insight into the pathophysiological role of CPPS in the cardiovascular system. Advances in CPP imaging enable investigation of key questions about the identity of cell types affected by CPPS in vivo or whether the detrimental effects of CPPS are limited to the cardiovascular system. These developments could culminate in the development of specific therapies targeting CPPS.

Clinical Relevance of CPPS: a Biomarker and Modifiable Risk Factor for Cardiovascular Pathology

The serum of patients with ESRD, coronary artery disease, or arterial hypertension has a greater propensity to CPP formation than serum from healthy blood donors. Increased propensity to generate CPPS is associated with adverse cardiovascular outcomes (i.e., all-cause and cardiovascular death, myocardial infarction, and peripheral artery disease) in patients with predialysis chronic kidney...
disease (CKD)\textsuperscript{9} and ESRD, including kidney transplant recipients.\textsuperscript{12,15} Moreover, the augmented propensity to form CPPs associates with the occurrence and progression of severe coronary artery calcifications and atherosclerotic cardiovascular events in patients with CKD stages 2 to 4.\textsuperscript{14,171} These observations were partially verified by findings of a recent study that patients with acute coronary syndrome have higher CPP serum levels than patients with stable angina (without predialysis CKD or ESRD) and serum CPP levels correlate with the total and lipid plaque volumes.\textsuperscript{7} Hence, serum CPP levels may be considered a surrogate marker of coronary atherosclerosis and coronary artery calcification. Meta-analyses demonstrating a link between reduced serum fetuin-A and albumin and a higher risk of coronary artery disease, additionally testify to the potential importance of elevated calcification propensity in the pathogenesis of atherosclerosis.\textsuperscript{199,199}

A method to determine calcification propensity has been developed which may be used for diagnostic approaches; CPP formation in patient serum is induced by supersaturating the serum with calcium and phosphate and measuring the optical density after incubation (Figure 2A). Other methods to quantify CPPs in serum and biofluids include microplate-based dynamic light-scattering and electron or atomic force microscopy. Microplate-based dynamic light scattering is both a high-throughput and precise method for estimating the hydrodynamic radius of nanoparticles and can be modified to detect CPPs.\textsuperscript{8} Alternatively, electron or atomic force microscopy are low-throughput but demonstrative methods for CPP visualization\textsuperscript{2,48} (Figure 2B). Alternatively, one-half maximal transition time has been established as a measure of primary-to-secondary CPP transition, and a prognostic biomarker in various patient cohorts (Figure 2C).\textsuperscript{9–15,79} Although this method provides a surrogate marker suggesting elevated CPP formation in disease, it remains unclear if all types of CPPs are equally detected, what their composition is, and whether the actual concentration of circulating CPPs is indeed elevated. Nonetheless, validation by independent groups of the association between a decreased one-half maximal transition time and the occurrence of pathology are ongoing.\textsuperscript{82,206,207} Despite their initial data indicates a successful reduction in CPP formation, their effects on long-term cardiovascular risk have yet to become apparent.

**Future Perspectives and Therapeutic Implications for CPPs in Cardiovascular Pathology**

The clinical relevance of elevated circulating CPP levels is illustrated by a significant correlation between an augmented calcification propensity or increased number of circulating CPPs and a higher risk of adverse outcomes, including major cardiovascular events and mortality.\textsuperscript{9–14} As CPPs represent a modifiable risk factor for cardiovascular diseases, pioneering clinical trials aimed at reducing the level of circulating CPPs are ongoing.\textsuperscript{82,206,207} Despite current advances in CPP research, revealing their clinical relevance to cardiovascular morbidity and primary modes of action, many questions remain unanswered.

First, we propose that the methods for obtaining CPPs require standardization, as their current nomenclature (Table), isolation techniques, and synthesis methods are diverse. CPP extraction from biological fluids is currently
Figure 2. Methods to detect calciprotein particles (CPPs) in clinical samples.

Supersaturation of serum with calcium chloride (CaCl₂) and sodium diphosphate (Na₂HPO₄) followed by incubation under culture conditions for 24 h causes the formation of CPPs that can be measured by absorbance at 650 nm. In disease conditions wherein CPP levels are increased, the OD₆₅₀ readings increase (A). Alternatively, CPPs can be pelleted by centrifugation and investigated by dynamic light scattering to assess particle size, electron and atomic force microscopy to assess morphology, or elemental analysis (EDX) to assess mineral constituent (B). Supersaturation of serum is also used to measure the one-half maximal transition time needed for amorphous-to-crystalline transition (T₅₀). An increased serum propensity for secondary CPP formation is observed as a reduction in T₅₀ (C). A novel flow cytometry-based technique allows for the direct quantification of CPP levels in serum. Here, serum precipitates are labeled with a combination of a fluorescent bisphosphonate (osteoSense) and a fluorescent membrane-intercalating dye (PKH67) and separated based on size, calcium phosphate content, and the presence of membranous lipids. CPPs are observed as OsteoSense+/PKH67− events that fluoresce dim compared to calcium phosphate crystal (CaP) crystals. CPPs are further characterized as primary- or secondary CPPs based on crystallinity (D). CMVs indicates calcifying microvesicles; ESRD, end-stage renal disease sample; HC, healthy control sample; MFI, mean fluorescence intensity; and OD, optical density.
Ca²⁺ and whether alternative protein-mineral particles under conditions of hyperphosphatemia is restricted to mine the protein composition. Combined with mass spectrometry approaches to determine structure, shape, crystallinity, and chemical composition would preferentially include the visualization of CPP size, by these physical and chemical features. This profiling effects, and their molecular mechanisms are defined they affect remains unclear. We strongly recommend performing in-depth characterization of CPPs’ physicochemical properties (eg, Ca²⁺, phosphate and protein content, particle size, and crystallinity) and comparing them to native CPPs isolated from patient sera, before using in vitro synthesized CPPs for mechanistic studies. Moreover, rather than the current multitude of protocols used to synthesize CPP in vitro, the research field would benefit from standardization.

Second, the current classification of CPPs into either primary (amorphous) or secondary (crystalline) particles may be oversimplified. CPPs can adsorb macromolecules from the ambient fluid and undergo dissolution-reprecipitation and ion exchange reactions. This leads to formation of a variety of different particles, not limited to certain sets hitherto defined as primary or secondary CPPs. Moreover, the exact shape, crystallinity, and chemical composition of CPPs within tissues are affected by several local factors including pH, amount, and relative proportion of available mineral ions, and the conformation of CPPs present in the vascular tissues they affect remains unclear. We strongly recommend comprehensive mineral and organic profiling as CPP effects, and their molecular mechanisms are defined by these physical and chemical features. This profiling would preferentially include the visualization of CPP size, structure, shape, crystallinity, and chemical composition combined with mass spectrometry approaches to determine the protein composition.

Third, it remains unclear whether particle formation under conditions of hyperphosphatemia is restricted to Ca²⁺ and whether alternative protein-mineral particles have pathophysiological properties like those of CPPs. Comparing the pathogenic effects of magnesium phosphate particles with the same size, shape, and organic profile as CPPs, we found that, unlike CPPs, these particles lack pathogenic capacity, suggesting that the pathogenic potential of CPPs is defined by its mineral component and possibly its crystallinity and not its proteinaceous constituents. Moreover, administration of CPPs produced using pyrophosphate—a phosphate substitute that does not allow for hydroxyapatite crystal formation—causes no pathogenic effects, suggesting that the specific crystals, and not the Ca²⁺ or phosphate, possess pathogenic capacity.

Fourth, current understanding of the signaling mechanisms evoked by CPP exposure is inadequate. Valuable information on the signaling mechanisms underlying CPP-mediated pathogenesis has been obtained from in vitro experiments (discussed in this review), but the observation that CPPs induce massive cell death in vitro but not in vivo suggests that CPP may evoke different signaling events in vitro and in vivo and may explain why current methodologies have been unable to identify clear alterations in signaling pathways. This illustrates the need to develop in vitro systems that mimic pathophysiology more closely. Furthermore, recent advances in high-throughput “-omics” approaches (RNA-sequencing, ribosome profiling, and mass spectrometry) will in the future provide a better insight into CPP-mediated signaling in primary vascular cells, as the lack of such data currently inhibits our understanding of cell-specific effects of CPPs and their involvement in pathogenesis. We propose that using single-cell RNA-sequencing can separate the process of cell death and other signaling events after exposure of vascular cell populations to CPPs. This approach can be complemented by combining CPP exposure with established cardiovascular risk factors (hypoxia, oxidized low-density lipoprotein cholesterol, advanced glycation end-products).

Regarding the in vivo studies reported to date, CPPs display different pathogenic behavior in animals and humans. In humans, elevated levels of CPPs have been primarily associated with increased vascular calcification, whereas in rodents CPP administration is associated with intimal hyperplasia and atherosclerosis and a highly variable frequency of vessel calcification. It should, however, be noted that the animal models currently used for CPP administration are normolipidemic, without a renal phenotype. Performing further studies to investigate the ability of CPPs to induce or aggravate vascular calcification would best be conducted in animal models that are predisposed to vascular calcification, such as partially nephrectomized rodents, or animals with dyslipidemia or inherently disturbed mineral homeostasis.

From clinical perspective, the elevation of circulating CPPs levels in patients with acute coronary syndrome compared with those with stable angina suggest possible importance of this parameter to prognosticate ischemic heart disease. Circulating CPP levels may also have prognostic value in other patient cohorts, including individuals with osteopenia/osteoporosis, primary hyperparathyroidism, or CKD, as these conditions are characterized by hypercalcemia and hyperphosphatemia, and the concentration of CPPs in the blood is closely reflected by patients’ mineralization status. As such, investigations into circulating CPP levels may explain the relationship between elevated bone turnover and the increased risk of cardiovascular disorders observed in these patients. Also, noteworthy, however, is that current investigations have focused primarily on measurement of calcification propensity rather than on direct detection of CPPs in the blood. The number of circulating CPPs may better predict cardiovascular
outcomes in these patients and would be a valuable addition to measuring calcification propensity.

From a translational perspective, pioneering studies using chelation therapy have established that circulating CPPs indeed represent a modifiable risk factor for cardiovascular outcome, although generalized chelation therapy has its limitations. Future research should focus on identifying Ca\(^{2+}\) chelators with a superior pharmacokinetic profile, or medicaments to facilitate the hepatic clearance of CPPs in patients at risk of developing cardiovascular events. For instance, Mg\(^{2+}\) has been recently suggested as a promising new therapeutic intervention in the development of CPP-induced vascular calcifications, as it dose-dependently delays maturation from primary to secondary CPPs and prevents VSMC calcification in vitro.\(^{212}\) Mg\(^{2+}\)-supplementation prevents and reverses the development of vascular calcifications in mice,\(^{211}\) making it a promising therapeutic intervention for patients with increased CPP levels.\(^{212}\) Replacement of calcium carbonate with lanthanum carbonate lowers serum CPP levels in patients with ESRD,\(^{213}\) which may explain its beneficial effect on the attenuation of aortic calcification.\(^{214}\) A recent study proposed 4,6-di-O-(methoxy-diethyleneglycol)-myo-inositol-1,2,3,5-tetrakis(phosphate)—an inositol phosphate analog—as an agent limiting primary-to-secondary CPP transition and preventing vascular calcification.\(^{215}\) These results suggest avenues for future clinical trials of crystalization inhibitors specifically targeting the formation of harmful secondary CPPs, at least in high-risk patients with CKD.

CONCLUSIONS

CPPs may be proposed as a relatively novel potential culprit of vascular disease which can be particularly important in patients with a comitant chronic kidney disease. Yet, exactly how CPPs influence vascular cells and cardiovascular pathology in vitro and vivo remains obscure. Upcoming research may uncover additional detrimental effects of CPPs, or pathways mediating the underlying pathophysiological mechanisms, whereas clinical investigations aim at direct identification of CPPs in the serum to evaluate their association with various cardiovascular pathologies. New insights into CPP-induced cardiovascular pathology will certainly lead to improved therapeutic interventions and possibly benefit cardiovascular outcome.

ARTICLE INFORMATION

Received September 9, 2020; accepted March 1, 2021.

Affiliations

Laboratory for Vascular Biology, Division of Experimental and Clinical Cardiology, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation (A.G.K., A.E.K., A.E.Y.), Department of Pathology and Medical Biology, Division of Pathology (L.F., J.-L.H.) and Laboratory for Cardiovascular Regenera-
Kutikhin AG, Velikanova EA, Mukhamadyarov RA, Glushkova TV, BorisovVV, Matveeva VG, Antonova LV, Filip'ev DE, Golovkin AS, Shishkova DK, et al. Apoptosis-mediated endothelial toxicity but not direct calcification or functional changes in anti-calcification proteins defines pathogenic effects of calcium phosphate biosign. Sci Rep. 2016;6:27255. doi: 10.1038/srep27255

Heiss A, Pipich V, Jahnens-Dechent W, Schwahn D. Fetuin-A is a mineral carrier protein: small angle neutron scattering provides new insight on Fetuin-A controlled calcification inhibition. Biochem Biophys Res Commun. 2010;393:396–399. doi: 10.1016/j.bbrc.2010.06.030

Luo G, Ducy P, McKee MD, Pirro GJ, Loyer E, Behrringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78–81. doi:10.1038/38678A0

Viegas CS, Viegas S, Santos S, Cavaco S, Neves J, et al. Glia-rich protein acts as a calcification inhibitor in the control of vascular calcification in the adult kidney. Arterioscler Thromb Vasc Biol. 2015;35:399–408. doi:10.1161/ATVBAHA.114.304829

Bekker KL. Vitamin K-dependent carboxylation. Vitam Horm. 2008;78:131–165. doi:10.1016/S0002-9440(07)00007-6

Schurgers LJ, Uitto J, Reutelingsperger CP. Vitamin K-dependent carboxylation of matrix Glα-protein: a crucial switch to control ectopic mineralization. Trends Mol Med. 2013;19:217–226. doi:10.1016/j.molmed.2012.12.008

Schurgers LJ, Xiao S, Cavaco S, Santos S, Amin R, et al. Nanoparticle conversion to biofilms: in vitro demonstrations using serum-derived mineral-organic nanoparticles. Nano Medicine (London). 2015;10:3519–3535. doi: 10.2217/nmn.15.1517

Fong P, Fares J, Gräber S, Wirth M, Richtering J, Hsu CY, Go AS, et al. Calcium-phosphate homeostasis: concerted interplay of new regulators. J Am Soc Nephrol. 2019;30:124–146. doi: 10.1681/ASN.2018050570

Herfs M, Theuwissen E, Vermeer C, Simes DC. Insights into the association of Glia-rich protein and osteoarthritis, novel splice variants and γ-carboxylation status. Mol Nutr Food Res. 2015;59:1636–1646. doi: 10.1002/mnrfs.201300941

Odermatt A, Wang X, Martin L, Flückiger S, et al. Macrophages influence mineralization of M001770200 secretory GCN in kidney transplant recipients. Atherosclerosis. 2019;291:351–353. doi:10.1016/j.atherosclerosis.2019.06.049
51. Kajander EO, Ciftçioglu N. Nanobacteria: an alternative mechanism for pathogenic intra- and extracellular calcification and stone formation. Proc Natl Acad Sci U S A. 1999;96:8274–8279. doi: 10.1073/pnas.96.15.8274

52. Richards JM, Kutikhin A, Schröder T, Placidi C, Schäfer C, Gräber S, Büscher A, Kutikhin A, Schmitt MM, Bornemann J, Nim Jermain F, Herrmann M, et al. Clearance of fetuin-A-containing calciprotein particles is mediated by scavenger receptor. A. Circ Res. 2012;111:579–584. doi: 10.1161/CIRCRESAHA.111.261479

53. Smith ER, Hanssens E, McMahon LP, Hoft SG. Fetuin-A-containing calciprotein particles reduce mineral stress in the macrophage. PLoS One. 2013;8:e60904. doi: 10.1371/journal.pone.0060904

54. Jäger E, Murthy S, Schmidt C, Hahn M, Strobel S, Peters A, Staubert C, Sungrur P, Venus T, Geisler M, et al. Calcium-sensing receptor-mediated NLRP3 inflammasome response to calciprotein particles drives inflammation in rheumatoid arthritis. Nat Commun. 2020;11:4243. doi: 10.1038/s41467-020-17749-6

55. Schreckenberg R, Schlüter KD. Calcium sensing receptor expression and signalling in cardiovascular physiology and disease. Vasc Pharmacol. 2018;107:35–42.

56. Huang LH, Sun XY, Ouyang JM. Shape-dependent toxicity and mineralization of endothelial cells in response to basic calcium phosphate nanoparticles in ATGR5- and ATGR6-deficient mouse cells. Sci Rep. 2019;9:19979. doi: 10.1038/s41598-019-55428-9

57. Ewence AE, Bootman M, Roderick HL, Skepper JN, McCarthy G, Epple M, Neumann M, Shanahan CM, Proudfoot D. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res. 2008;103:e28–e34. doi: 10.1161/01.RES.0000340784.44441.7a

58. Hunter LW, Charlesworth JE, Yu S, Lieske JC, Miller VM. Calcifying nanoparticles promote mineralization and mechanical forces. J R Soc Interface. 2011;8:103–115. doi: 10.1038/jri.2010.178

59. Jäger E, Murthy S, Heiss A, Gräber S, Büscher A, Herrmann M, Schäfer C, Heiss A, Gräber S, Kinkeldey A, Büscher A, Herrmann M, et al. CALR and mitochondrial Ca²⁺ transport in the endothelium: regulation by ions, redox signalling and mechanical forces. J R Soc Interface. 2014;11:20130125. doi: 10.1098/rsif.2014.0125

60. Kajander EO, Ciftçioglu N. Nanobacteria: an alternative mechanism for pathogenic intra- and extracellular calcification and stone formation. Proc Natl Acad Sci U S A. 1999;96:8274–8279. doi: 10.1073/pnas.96.15.8274

61. Liu Z, Xiao Y, Chen W, Wang Y, Wang B, Wang G, Xu X, Tang R. Calcium phosphate nanoparticles primarily induce cell necrosis through lyso-somol rupture: the origination of material cytotoxicity. J Mater Chem B. 2014;2:3480–3489. doi: 10.1039/c4tb00056k

62. Hunter LW, Charlesworth JE, Yu S, Lieske JC, Miller VM. Calcifying nanoparticles promote mineralization in vascular smooth muscle cells: implications for atherosclerosis. J Int Med. 2014;275:2689–2698. doi: 10.1111/j.1365-2702.2012.05617.x

63. Dautova Y, Kovalova A, Dzepkier NV, Epple M, Bootman MD, Proudfoot D, Fetuin-A and receptor activator of NF-κB receptor modify cytosolic calcium transients on vascular human smooth muscle cells. PLoS One. 2014;9:e97565. doi: 10.1371/journal.pone.0097565

64. Shishkova D, Velikanova E, Sinišký M, Tsepokina A, Gruzdeva O, Bogdanov L, Kutikhin A. Calcium phosphate ions cause internal hyperplasia in intact aortas of normolipemic rats through endothelial repair. Int J Mol Sci. 2019;20:5726.

65. Callegrari A, Coons ML, Ricks JL, Rosenfeld ME, Scatena M. Increased permeability of basic calcium phosphate crystals via protein kinase C and MAPK pathways: a vicious cycle of inflammation and arterial calcification? Arterioscler Thromb Vasc Biol. 2015;35:2044–2052. doi: 10.1161/ATVBAHA.108.305908

66. Eelderink C, Te Veldheijer H, Vos J, Verdonck S, De Doncker H, Stroobants S, et al. Effect of phosphate on vascular function under normal conditions and influence of the uraemic state. Cardiovasc Res. 2012;96:130–139. doi: 10.1093/cvr/cvs240

67. Smith ER, Pan FFM, Hewitson TD, Toussaint ND, Hoft SG. Effect of sevelamer on calciprotein particles in hemodialysis patients: the sevelamer versus calcium to reduce Fetuin-A-containing calciprotein particles in dialysis (ScaFARP) randomized controlled trial. Kidney Int Rep. 2020;5:1432–1447. doi: 10.1016/j.ekint.2020.06.014

68. Szemes KK, Denly L, Pachter MD, Mark PB, Kettlewell S, Smith GL, Clancy MJ, Delles C, Jardine AG. Deletional effects of phosphate on vascular function via disruption to the nitric oxide pathway. Nephrol Dial Transplant. 2017;32:1617–1627. doi: 10.1093/ndt/gfw252

69. Horng C, Chen JC, Huang Z, Cui S, Wang L, Fu B, Deng R, Yang J, Chen X, et al. Hyperuricemia induces endothelial dysfunction via mitochondrial Na⁺/Ca²⁺ exchanger-mediated mitochondrial calcium overload. Cell Calcium. 2015;51:402–410. doi: 10.1016/j.ceca.2015.03.003

70. Márquez RM, Belaisi A, Roggi P. Cardiovascular biomarkers in chronic kidney disease: state of current research and clinical applicability. Dis Markers. 2015;2015:586569. doi: 10.1155/2015/586569

71. Speyr MV, Yang HY, Brabb T, Leaf E, Akin L, Wilkin A, Dichek D, Giachelli CM. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcified arteries. Circ Res. 2008;103:733–741. doi: 10.1161/01.RES.0000308503

72. Eelderink C, Te Veldheijer H, Vos J, Verdonck S, De Doncker H, Stroobants S, et al. Effect of phosphate on vascular function under normal conditions and influence of the uraemic state. Cardiovasc Res. 2012;96:130–139. doi: 10.1093/cvr/cvs240

73. Wang Q, Wang L, Zhang T, Wang Y. Calcium-sensing receptor activation of vascular smooth muscle cells: dependence on receptor activator of NF-κB ligand and interleukin 6. J Vasc Res. 2014;51:118–131. doi: 10.1159/000358920

74. Peng HH, Wu CY, Young D, Martel J, Young O, Ocius DM, Lee YH, Young JD. Physicochemical and biological properties of biomimetic mineral-polymer nanoparticles formed from calcium and biological salts. Small. 2019;15:2927–3028. doi: 10.1002/smll.2017020270

75. Dada LA, Snajder JI. Mitochondrial Ca⁴⁺ and ROS take center stage to orchestrate TNF-α-mediated inflammatory responses. J Clin Invest. 2011;121:1683–1685. doi: 10.1172/JCI57748

76. Alexioudou BR, Shannaghaqy A, Patel A, Stathopoulos PB, Madesh M. Mitochondrial Ca²⁺ transport in the endothelium: regulation by ions, redox signaling and mechanical forces. J Physiol Sci Interface. 2017;14:20170762.

77. Morgan MJ, Liu ZG. Crossstalk of reactive oxygen species and NF-κB signaling. Cell Res. 2011;21:103–115. doi: 10.1038/cr.2010.178

78. Campillo-Giménez L, Renaudin F, Jalabert M, Gras P, Gossel M, Roy C, Sarda S, Collet C, Cohen-Solal M, Combès C, et al. Inflammatory potential of four different phases of calcium pyrophosphate relies on NF-κB activation and MAPK pathways. Front Immunol. 2019;9:2248. doi: 10.3389/fimmu.2018.02248

79. Kutikhin et al. CalciproteinParticles inVascularPathology.
92. Li X, Lim J, Lu J, Pedego TM, Demer L, Tintut Y. Protective role of Smad5 in inflammation-induced vascular cell calcification. J Cell Biochem. 2015;116:2354–2364. doi: 10.1002/jcb.25186

93. Durham AL, Speer MY, Scatena M, Giachelli CM, Shanahan CM. Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness. Cardiovasc Res. 2018;114:590–600. doi: 10.1093/cvr/cvy105

94. Tintut Y, Parhami F, Boström K, Jackson SM, Demer LL. cAMP stimulates osteoblast-like differentiation of calcifying vascular cells. Potential signaling pathway for vascular calcification. J Biol Chem. 1998;273:7547–7553. doi: 10.1074/jbc.273.13.7547

95. Jaminon A, Reesink K, Kroon A, Schurgers L. The role of vascular smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness. Circulation. 2002;106:3044–3050. doi: 10.1161/01.cir.0000041429.83465.41

96. Nishimura R, Yoneda T, Ichida K, Ishida F, Sakaue T, Murohara K, Miura A, Itahana K, Ohtani K, Kihara S, et al. Calcification in aortic calcium deposits in aged hyperlipidemic mice. Arterioscler Thromb Vasc Biol. 2021;41:e185–e192. doi: 10.1161/ATVBAHA.120.315737

97. Meine H, Granäsen G, Wiklund U, Schermund A, Guerci A, Erbel R, Raggi P. High dose and long-term statin therapy accelerate coronary artery calcification. Int J Cardiol. 2015;184:581–586. doi: 10.1016/j.ijcard.2015.02.072

98. Aghaeeei A, Bahn G, Reaven PD; VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2012;35:2390–2392. doi: 10.2337/dc12-0464

99. Tang YG, Inoue I, Inoue K, Shinoda Y, Ida S, Goto S, Nakano T, Shimada A, Noda M. The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy. NPJ Aging Mech Dis. 2018;4:7. doi: 10.1038/s41514-018-0026-2

100. Achenbach S, Ropers D, Pohle K, Leber A, Thilo C, Kneze M, Menendez T, Maertfett R, Kusus M, Regenfus M, et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation. 2002;106:1077–1082. doi: 10.1161/01.cir.0000027576.49283.f8

101. Rifai MA, Blaha MJ, Patel J, Xiaoming J, Cainsz-Achirica M, Greenland P, Budoff M, Yeboah J, Nasir K, Al-Mallah MH, et al. Coronary artery calcification, statin use and long-term risk of atherosclerotic cardiovascular disease events (from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol. 2020;126:835–839. doi: 10.1016/j.amjcard.2019.12.031

102. Imai Y, Nakagawa T, Tamae I, Sato J, Watanabe H, Ohashi T, Imai Y, Nakano T, Kishida T, et al. Antiinflammatory effects of statins in experimental chronic kidney disease. Am J Pathol. 2018;184:2727–2736. doi: 10.1016/j.ajpath.2018.06.016

103. Matsuoka T, Kida K, Yamaguchi A, Hata K, Ichida F, Meguro H, Aburatan H, Nishimura Y, Roneda T. BMP2 regulates osteoblast differentiation induced by vitamin D3 to protect the calcification of vascular smooth muscle cells. Calcif Tissue Int. 2015;96:285–295. doi: 10.1007/s00223-014-9875-1

104. Aghaeeei A, Bahn G, Reaven PD; VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2012;35:2390–2392. doi: 10.2337/dc12-0464

105. Achenbach S, Ropers D, Pohle K, Leber A, Thilo C, Kneze M, Menendez T, Maertfett R, Kusus M, Regenfus M, et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation. 2002;106:1077–1082. doi: 10.1161/01.cir.0000027576.49283.f8

106. Imai Y, Nakagawa T, Tamae I, Sato J, Watanabe H, Ohashi T, Imai Y, Nakano T, Kishida T, et al. Antiinflammatory effects of statins in experimental chronic kidney disease. Am J Pathol. 2018;184:2727–2736. doi: 10.1016/j.ajpath.2018.06.016

107. Aghaeeei A, Bahn G, Reaven PD; VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2012;35:2390–2392. doi: 10.2337/dc12-0464

108. Achenbach S, Ropers D, Pohle K, Leber A, Thilo C, Kneze M, Menendez T, Maertfett R, Kusus M, Regenfus M, et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation. 2002;106:1077–1082. doi: 10.1161/01.cir.0000027576.49283.f8

109. Imai Y, Nakagawa T, Tamae I, Sato J, Watanabe H, Ohashi T, Imai Y, Nakano T, Kishida T, et al. Antiinflammatory effects of statins in experimental chronic kidney disease. Am J Pathol. 2018;184:2727–2736. doi: 10.1016/j.ajpath.2018.06.016

110. Achenbach S, Ropers D, Pohle K, Leber A, Thilo C, Kneze M, Menendez T, Maertfett R, Kusus M, Regenfus M, et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation. 2002;106:1077–1082. doi: 10.1161/01.cir.0000027576.49283.f8

111. Xian JZ, Lu M, Fong F, Giao R, Patel NR, Aberdeena D, Irissa S, Demer LL, Tintut Y. Statin effects on vascular calcification: microarchitectural changes in aortic calcium deposits in aged hyperlipidemic mice. Arterioscler Thromb Vasc Biol. 2021;41:e185–e192. doi: 10.1161/ATVBAHA.120.315737

112. Li X, Lim J, Lu J, Pedego TM, Demer L, Tintut Y. Statin effects on vascular calcification: microarchitectural changes in aortic calcium deposits in aged hyperlipidemic mice. Arterioscler Thromb Vasc Biol. 2021;41:e185–e192. doi: 10.1161/ATVBAHA.120.315737

113. Kutikhin et al Calciprotein Particles in Vascular Pathology

Arterioscler Thromb Vasc Biol. 2021;41:1607–1624. doi: 10.1161/ATVBAHA.120.315697

May 2021
1621
128. Zickler D, Luecht C, Willy K, Chen L, Witowski J, Girndt M, Fiedler R, Storr M, Kambie-Mitz J Schoon J, et al. Tumour necrosis factor-alpha in uraemic serum promotes osteoblastic transition and calcification of vascular smooth muscle cells via extracellular signal-regulated kinases and activator protein 1/2-FOG-mediated induction of interleukin 6 expression. Nephrol Dial Transplant. 2018;33:576–585. doi: 10.1093/ndt/gfx316
129. Li X, Yang HY, Giachelli CM. BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis. 2008;199:271–277. doi: 10.1016/j.atherosclerosis.2007.11.031
130. Liberman M, Johnson RC, Handy DE, Loscalzo J, Leopold JA. Bone morphogenetic protein-2 activates NADPH oxidase to increase endothelial reticulum stress and human coronary artery smooth muscle cell calcification. Biochem Biophys Res Commun. 2011;413:436–441. doi: 10.1016/j.bbrc.2011.08.114
131. Byron CH, Javed A, Dai Q, Kappes JC, Clemens TL, Darley-Usmar VM, Byon CH, Javed A, Dai Q, Kappes JC, Clemens TL, Darley-Usmar VM, Blanc A, Pandey NR, Srivastava AK. Distinct roles of Ca2+, calmodulin, and protein kinase C in H2O2-induced activation of ERK1/2, p38 MAPK, and protein kinase D signaling in vascular smooth muscle cells. Antioxid Redox Signal. 2004;6:353–366. doi: 10.1089/152308604322899422
132. Zhao MM, Xu MJ, Cai Y, Zhao G, Guan Y, Kong W, Tang C, Wang X. Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high-phosphate-induced vascular calcification in vitro and in vivo. Kidney Int. 2011;79:1071–1079. doi: 10.1038/ki.2011.18
133. Kurzumi A, Nakao K, Yamagata K, Oyuda N, Nakayama S, Tanaka Y, IL-6 and sIL-6R induced TAT3-dependent differentiation of human VSMCs into osteoblast-like cells through JMDJ2B-mediated histone demethylation of RUNX2. Bone. 2019;124:53–61. doi: 10.1016/j.bone.2019.04.006
134. Price PA, Caputo JM, Williamson MK. Discovery of a high molecular weight complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment. J Biol Chem. 2016;291:53094–53107. doi: 10.1074/jbc.M116.742411
135. Khosla S, Altman RB, Ensrud KE, Kropf P, Cauley JA, Black DM, Kiel DP, Walford GL, Danielson K, et al. Hydroxyapatite nanoparticles and vascular response to injury in rabbit carotid arteries: proof of principle. J Vasc Res. 2012;49:1–12. doi: 10.1515/jvr-2011-0328
136. Schwart MA, Lieske JC, Kumar V, Farell-Baril G, Miller VM. Human-derived nanoparticles and vascular response to injury in rabbit carotid arteries: proof of principle. Int J Nanomedicine. 2008;3:243–248. doi: 10.2147/inj.n2473
137. Chen NX, O’Neill K, Chen X, Klattsunthorn K, Gattone VH, Moe SM. Transglutaminase 2 accelerates vascular calcification in chronic kidney disease. Am J Nephrol. 2013;37:191–198. doi: 10.1159/000347033
138. Rogers MA, Buffol O, Schlott F, Atkins SK Lee LH, Halu A, Blaser MC, Tsolaki E, Higashi H, Luther K, et al. Annexin a1-dependent tethering promotes extracellular vesicle exosome-mediated mineralization revealed with single-extracellular vesicle analysis. Sci Adv. 2020;6:eabb1244.
139. Schlieper G, Schurgers L, Brandenburg V, Reutelingsperger C, Floege J. Annexin-induced exosome secretion. J Biol Chem. 2002;277:12050–12055. doi: 10.1074/jbc.M102038200
140. attractive E, Extracellular vesicles in cardiovascular disease: focus on vascular calcification. J Physiol. 2016;594:2977–2980. doi: 10.1113/JP272112
165. Boulanger CM, Loyer X, Rautou PE, Amabile N. Extracellular vesicles in coronary artery disease. Nat Rev Cardiol. 2017;14:259–272. doi: 10.1038/nrcardio.2017

166. Cui L, Houston DA, Farquharson C, MacRae VE. Characterisation of matrix vesicles in skeletal and soft tissue mineralisation. Bone. 2016;87:147–158. doi: 10.1016/j.bone.2016.04.007

167. Dusso A, Colombo MI, Shanahan CM. Not all vascular smooth muscle cell exosomes calcify equally in chronic kidney disease. Kidney Int. 2019;83:298–301. doi: 10.1016/j.kint.2017.08.036

168. Otsuka F, Sakakura K, Yahagi K, Joner M, Virmani R. Has our understanding of calcification in human coronary atherosclerosis progressed? Arterioscler Thromb Vasc Biol. 2014;34:724–736. doi: 10.1161/ATVBAHA.113.302642

169. Proudfoot D, Skepper JN, Hegyi L, Bennett MR, Shanahan CM, Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Bundy JD, Cai X, Scialla JJ, Dobre MA, Chen J, Hsu CY, Leonard MB, Qi XY, Qu SL, Xiong WH, Rom O, Chang L, Jiang ZS. Perivascular adipose tissue (PVAT) in atherosclerosis: a double-edged sword. Cardiovasc Res. 2016;105:1055–1062. doi: 10.1093/cvr/cvs105

170. Ahmedieh S, Kim HW, Weintrub NL. Potential role of perivascular adipose tissue in modulating atherosclerosis. Cln Sc (Lon). 2020;19:334–13. doi: 10.1042/C20190577

171. Qi XY, Qu SL, Xiong WH, Rom O, Chang L, Jiang ZS. Perivascular adipose tissue (PVAT) in atherosclerosis: a double-edged sword. Cardiovasc Res. 2016;105:1055–1062. doi: 10.1093/cvr/cvs105

172. Shields KJ, El Khoudary SR, Aheam JM, Manzi S. Association of aortic perivascular adipose tissue density with aortic calcification in women with systemic lupus erythematosus. Atherosclerosis. 2017;262:55–61. doi: 10.1016/j.atherosclerosis.2017.04.021

173. Sun ZL, Xie QY, Guo GL, Ma K, Huang YY. Serum fetuin-A levels in patients with cardiovascular disease: a meta-analysis. Cardiovasc Res. 2016;105:1055–1062. doi: 10.1093/cvr/cvs105

174. Ismaeel K, Farajollahi M, Antoniades C. Computed tomography-based perivascular fat phenotyping identifies unstable coronary lesions. J Cell Mol Med. 2021;25:1808–1816. doi: 10.1111/jcmm.16150

175. Kutikhin et al. Calciprotein Particles in Vascular Pathology. Arterioscler Thromb Vasc Biol. 2021;41:1607–1624. DOI: 10.1161/ATVBAHA.120.315697 May 2021 1623

176. Singh S, Torzewski M. Fibroblasts and their pathological functions in the fibrosis of aortic valve sclerosis and atheromatosus. Biomolecules. 2019;9:472

177. Dutzmann J, Koch A, Weisheit S, Sonnenschein K, Korte L, Haertlé T, Thum T, Bauersachs J, Sedding DG, Daniel JM. Sonic hedgehog-dependent activation of adventitial fibroblasts promotes neointima formation. Cardiovasc Res. 2017;113:1653–1663. doi: 10.1093/cvr/cvx158

178. Zhu Z, Hao X, Li T, Guo J. Homeostatine promotes migration of adventitial fibroblasts via angiotensin ii type 1 receptor activation to aggravate atherosclerosis. BMC Cardiovasc Diord. Preprint posted online December 17, 2020. doi: 10.21203/rs.3.rs-32632/v3. https://www.researchsquare.com/article/rs.3/rs-32632/v3

179. Yuan F, Wang D, Xu K, Wang J, Zhang Z, Yang L, Yang GY, Li S. Contribution of vascular cells to neointimal formation. PLoS One. 2017;12:e0168914. doi: 10.1371/journal.pone.0168914

180. Krishnan P, Purushothaman KR, Purushothaman M, Turnbull IC, Tarricone A, Vasquez M, Jain S, Baber U, Lascano RA, Kini AS, et al. Enhanced neointimal fibroblast, myofibroblast content and altered extracellular matrix composition: implications in the progression of human peripheral artery restenosis. Atherosclerosis. 2016;251:226–233. doi: 10.1016/j.atherosclerosis.2016.06.046

181. Jabs A, Okamoto E, Vinten-Johansen J, Bauriedel G, Wilcoxon JN. Sequential patterns of chemokine- and chemokine receptor-synthesis following vesel wall injury in porcine coronary arteries. Atherosclerosis. 2007;192:75–84. doi: 10.1016/j.atherosclerosis.2006.05.050

182. Miltufovíc A, Šuput D, Zorc-Plsekovíc R. Pathogenesis of atherosclerosis in the lunaica intima, media, and adventitia of coronary arteries: an updated review. J Clin Basic Med Sci. 2020;2021:30–90. doi: 10.17305/jcbms.2019.4320

183. Sartore S, Chiavegato A, Faggion E, Franchi R, Putoz M, Ausoni S, Pauletto P. Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ Res. 2001;89:1111–1121. doi: 10.1161/01.hra.89.8.1111

184. Xu F, Ji J, Li L, Chen R, Hu W. Activation of adventitial fibroblasts contributes to the early development of atherosclerosis: a novel hypothesis that complements the "Response-to-Injury Hypothesis" and the "Inflammation Hypothesis". Med Hypotheses. 2007;69:908–912. doi: 10.1016/j.mehy.2007.01.062

185. Li N, Cheng W, Huang T, Yuan J, Wang X, Song M. Vascular adventitial calcification and its underlying mechanism. PLoS One. 2015;10:e0132506. doi: 10.1371/journal.pone.0132506

186. Cai MXX, Smith ER, Kent A, Huang L, Hewittson TD, McMahon LP, Holt SG. Calciprotein particle formation in peritoneal dialysis effluent is dependent on dialysate calcium concentration. Pitol Dial Int. 2018;38:286–292. doi: 10.1077/pdi.2017.00163

187. Allahverdian S, Chabane C, Boukais K, Francis GA, Bochaton-Piallat ML. Smooth muscle cell fate and plasticity in atherosclerosis. Cardiovasc Res. 2018;114:545–550. doi: 10.1093/cvr/cvy022

188. Danesh J, Whincup P, Walker M, Lennon A, Thornson A, Appleby P, Gallimore JR, Pepsy MB. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199–204. doi: 10.1136/bmj.321.7255.199

189. Sun ZL, Xie QY, Guo GL, Ma K, Huang YY. Serum fetuin-A levels in patients with cardiovascular disease: a meta-analysis. Biomed Res Int. 2014;2014:691540. doi: 10.1155/2014/691540

190. Bleisez B, Reiter T, Marquescu R, Glessia A, Bojic M, Kieweg H, Cejka O. Calcification propensity of serum is independent of excretory renal function. Scit Rep. 2017;7:19491. doi: 10.1038/s41598-017-18336-4

191. Aigner C, Cejka D, Silber C, Frauschel M, Sunder-Plassmann G, Gaggi M. Oral sodium bicarbonate supplementation does not affect serum calcium, magnesium, calcium and phosphate in patients with chronic kidney disease and chronic metabolic acidosis. Kidney Blood Press Res. 2019;44:189–199. doi: 10.1159/000498975

192. Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Lindblad L, Lewis EF, Drisko J, Lee KL; TACT Investigators. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA. 2013;309:1241–1249. doi: 10.1001/jama.2013.21207

193. Escolar E, Lamas GA, Mark DB, Boineau R, Goertz C, Rosenberg Y, Nahin RL, Ouyang P, Rozema T, Magaziner A, et al. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). Cardiovasc Diord. 2014;7;15–24. doi: 10.1111/CIRCTOUTCOMES.13.000665
203. Ujueta F, Arenas IA, Escolar E, Diaz D, Boineau R, Mark DB, Golden P, Lindblad L, Kim H, Lee KL, et al. The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trial to Assess Chelation Therapy (TACT). J Diabetes Complications. 2019;33:490–494. doi: 10.1016/j.diabcomp.2019.04.005

204. Avila MD, Escolar E, Lamas GA. Chelation therapy after the trial to assess chelation therapy: results of a unique trial. Curr Opin Cardiol. 2014;29:481–488. doi: 10.1097/HCO.0000000000000096

205. Foreman H, Trujillo TT. The metabolism of C14 labeled ethylenediaminetetraacetic acid in human beings. J Lab Clin Med. 1954;43:566–571.

206. Quiñones H, Hamdi T, Sakhaee K, Pasch A, Moe OW, Pak CYC. Control of metabolic predisposition to cardiovascular complications of chronic kidney disease by effervescent calcium magnesium citrate: a feasibility study. J Nephrol. 2019;32:99–100. doi: 10.1007/s40660-018-0559-2

207. Bressendorff I, Hansen D, Schou M, Silver B, Pasch A, Bouchelouche P, Pedersen L, Rasmussen LM, Brandi L. Oral magnesium supplementation in chronic kidney disease stages 3 and 4: efficacy, safety, and effect on serum calcification propensity-A prospective randomized double-blinded placebo-controlled clinical trial. Kidney Int Rep. 2017;2:380–389. doi: 10.1016/j.ekir.2016.12.008

208. Wu CY, Martel J, Young JD. Comprehensive organic profiling of biological particles derived from blood. Sci Rep. 2018;8:11310. doi: 10.1038/s41598-018-29573-6

209. Cottignoli V, Relucenti M, Agrostì G, Cavarretta E, Familiari G, Salvador L, Maras A. Biological niches within human calcified aortic valves: towards understanding of the pathological biomineralization process. Biomed Res Int. 2015;2015:542687. doi: 10.1155/2015/542687

210. Holt SG, Smith ER. Fetuin-A-containing calciprotein particles in mineral trafficking and vascular disease. Nephrol Dial Transplant. 2016;31:1583–1587. doi: 10.1093/ndt/gfw048

211. Diaz-Tocados JM, Peralta-Ramírez A, Rodríguez-Ortiz ME, Raya Al, Lopez I, Pineda C, Herencia C, Montes de Oca A, Vergara N, Steppan S, et al. Dietary magnesium supplementation prevents and reverses vascular and soft tissue calcifications in uremic rats. Kidney Int. 2017;92:1084–1099. doi: 10.1016/j.kint.2017.04.011

212. Bressendorff I, Hansen D, Pasch A, Holt SG, Schou M, Brandi L, Smith ER. The effect of increasing dialysate magnesium on calciprotein particles, inflammation and bone markers: post hoc analysis from a randomized controlled clinical trial. Nephrol Dial Transplant. 2019;34:gfz234. doi: 10.1093/ndt/gfz234.

213. Nakamura K, Nagata Y, Hiroyoshi T, Isoyama N, Fujikawa K, Miura Y, Matsuyma H, Kuro-O M. The effect of lanthanum carbonate on calciprotein particles in hemodialysis patients. Clin Exp Nephrol. 2020;24:323–329. doi: 10.1007/s10157-019-01832-4

214. Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology (Carlton). 2011;16:290–298. doi: 10.1111/j.1440-1797.2010.01412.x

215. Schantl AE, Verhulst A, Neven E, Behets GJ, D’Haese PC, Maillard M, Mordini D, Phan O, Burnier M, Spaggiari D, et al. Inhibition of vascular calcification by inositol phosphates derivatized with ethylene glycol oligomers. Nat Commun. 2020;11:721. doi: 10.1038/s41467-019-14091-4